The combination of immunotherapies improves survival with respect to various types of cancer. 48% of kidney cancer patients treated on the first line with the combination of the immunotherapy molecules nivolumab and ipilimumab are alive at 5 years. An important result for these patients. And in mesothelioma, 23% are alive at 3 years, again thanks to this approach in patients never treated before. Again this is a result that oncologists define as “unique”.
The data comes from the CheckMate -214 and CheckMate -743 studies, presented at the Congress of the European Society of Medical Oncology (ESMO) and detailed today in a virtual press briefing sponsored by Bristol Myers Squibb.
In 2020, 13,500 new cases of kidney cancer were estimated in Italy and more than 144,000 people live after diagnosis. The most frequent form is that of kidney cells.
“Over 50% of patients with early stage disease recover – says Carmine Pinto, Director of Medical Oncology Comprehensive Cancer Center AUSL-IRCCS of Reggio Emilia -. However, 30% arrive at the diagnosis already at an advanced stage and, in a third, the disease can recur in metastatic form after surgery. Historically, 5-year survival in advanced or metastatic disease did not exceed 13%. Today, however, thanks to the combination of the two immuno-oncological molecules, almost half are alive at 5 The Phase 3 CheckMate -214 study involved 1,096 patients. The combination of immunotherapy improves and therefore significantly extends the long-term life expectancy for these patients. ” The combination also showed improvements in overall survival in six Phase 3 studies involving 5 different cancers: in addition to renal cell carcinoma, non-small cell lung cancer, melanoma, squamous cell esophageal cancer and pleural mesothelioma.
(ANSA).
breaking latest news © Copyright ANSA
.